Literature DB >> 26743200

Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.

Allison Mah1, Alissa Wright2.   

Abstract

The incidence of end-stage liver disease (ESLD) is increasing and many of these patients may be considered for orthotopic liver transplantation. As patients with ESLD are at risk of a number of infections, infectious disease physicians should be aware of the management of these infections in order to provide optimal patient care and ensure transplantation success. We present a review of the literature pertaining to infectious disease considerations in the liver transplant candidate. It highlights several topics with recent developments including the management of hepatitis C virus infection prior to transplantation, treatment of hepatitis B virus infection, colonization and infection with multidrug resistant organisms, and management of spontaneous bacterial peritonitis.

Entities:  

Keywords:  Cirrhosis; Decolonization; Hepatitis B; Hepatitis C; Infection; Liver; Multidrug resistant organisms; Spontaneous bacterial peritonitis; Transplantation

Year:  2016        PMID: 26743200     DOI: 10.1007/s11908-015-0514-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  72 in total

Review 1.  Hepatitis C treatment in patients on the liver transplant waiting list.

Authors:  Elizabeth C Verna; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

2.  OPTN/SRTR 2013 Annual Data Report: liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

Review 3.  Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.

Authors:  Shawn Vasoo; Jason N Barreto; Pritish K Tosh
Journal:  Mayo Clin Proc       Date:  2015-03       Impact factor: 7.616

4.  Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.

Authors:  Brett E Fortune; Alvaro Martinez-Camacho; Sarah Kreidler; Jane Gralla; Gregory T Everson
Journal:  Transpl Int       Date:  2015-04-16       Impact factor: 3.782

5.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

7.  A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Gregory T Everson; Norah A Terrault; Anna S Lok; Del R Rodrigo; Robert S Brown; Sammy Saab; Mitchell L Shiffman; Abdullah M S Al-Osaimi; Laura M Kulik; Brenda W Gillespie; James E Everhart
Journal:  Hepatology       Date:  2013-01-17       Impact factor: 17.425

Review 8.  Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update.

Authors:  Jose M Miro; Peter Stock; Elina Teicher; Jean-Charles Duclos-Vallée; Norah Terrault; Antoni Rimola
Journal:  J Hepatol       Date:  2014-10-30       Impact factor: 25.083

9.  A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage.

Authors:  Lisa Saidel-Odes; Hana Polachek; Nehama Peled; Klaris Riesenberg; Francisc Schlaeffer; Yafa Trabelsi; Seada Eskira; Baha Yousef; Rozalia Smolykov; Shlomi Codish; Abraham Borer
Journal:  Infect Control Hosp Epidemiol       Date:  2011-11-30       Impact factor: 3.254

10.  The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.

Authors:  Manuela Merli; Cristina Lucidi; Vincenza Di Gregorio; Marco Falcone; Valerio Giannelli; Barbara Lattanzi; Michela Giusto; Giancarlo Ceccarelli; Alessio Farcomeni; Oliviero Riggio; Mario Venditti
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

View more
  2 in total

Review 1.  Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.

Authors:  Tomohide Hori; Yasuhiro Ogura; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Motoshi Kainuma; Hideo Takahashi; Shogo Suzuki; Takashi Ichikawa; Shoko Mizuno; Tadashi Aoyama; Yuki Ishida; Takahiro Hirai; Tomoko Hayashi; Kazuko Hasegawa; Hiromu Takeichi; Atsunobu Ota; Yasuhiro Kodera; Hiroyuki Sugimoto; Taku Iida; Shintaro Yagi; Kentaro Taniguchi; Shinji Uemoto
Journal:  World J Hepatol       Date:  2016-09-08

2.  Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt.

Authors:  Ahmed Mohamed Saleh; Essam Ali Hassan; Ahmed Ali Gomaa; Tamer Mahmoud El Baz; Mohamed El-Abgeegy; Mohamed Ismail Seleem; Yousry Esam-Eldin Abo-Amer; Heba Fadl Elsergany; Eman Ibrahim El-Desoki Mahmoud; Sherief Abd-Elsalam
Journal:  Infect Drug Resist       Date:  2019-07-24       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.